clinical trial · NCT03069469
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC·phase2·active not recruiting·n = 120
Advanced Malignant NeoplasmPigmented Villonodular SynovitisGiant Cell Tumor of Tendon SheathTenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, DiffuseVimseltinib
brief summary
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
started
Feb 16, 2017
primary completion
Jul 1, 2026
completion
Aug 1, 2028
last updated
Dec 18, 2025
official title
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol